RespireRx Pharmaceuticals Inc. (RSPI)
USD 0.0
(15.0%)
USD 0.0
(15.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -3.97 Million USD | 47.74% |
| 2021 | -3.86 Million USD | 20.16% |
| 2020 | -4.84 Million USD | -92.36% |
| 2019 | -2.51 Million USD | 2.78% |
| 2018 | -2.59 Million USD | 39.61% |
| 2017 | -4.29 Million USD | 53.5% |
| 2016 | -9.22 Million USD | -54.81% |
| 2015 | -5.96 Million USD | -120.2% |
| 2014 | -2.7 Million USD | -125.35% |
| 2013 | -1.2 Million USD | 84.13% |
| 2012 | -7.57 Million USD | -235.82% |
| 2011 | -2.25 Million USD | -238.44% |
| 2010 | 1.62 Million USD | 119.29% |
| 2009 | -8.44 Million USD | 42.17% |
| 2008 | -14.59 Million USD | -12.54% |
| 2007 | -12.96 Million USD | 19.22% |
| 2006 | -16.05 Million USD | -38.34% |
| 2005 | -11.6 Million USD | 0.0% |
| 2004 | - USD | 100.0% |
| 2003 | -1.17 Million USD | -19.56% |
| 2002 | -982.63 Thousand USD | 63.24% |
| 2001 | -2.67 Million USD | -1254.26% |
| 2000 | -197.4 Thousand USD | 87.83% |
| 1999 | -1.62 Million USD | 69.16% |
| 1998 | -5.25 Million USD | -6.65% |
| 1997 | -4.92 Million USD | -18.56% |
| 1996 | -4.15 Million USD | 38.85% |
| 1995 | -6.8 Million USD | -44.68% |
| 1994 | -4.7 Million USD | -487.5% |
| 1993 | -800 Thousand USD | 66.67% |
| 1992 | -2.4 Million USD | 7.69% |
| 1991 | -2.6 Million USD | -18.18% |
| 1990 | -2.2 Million USD | -83.33% |
| 1989 | -1.2 Million USD | -344.44% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -537.02 Thousand USD | -69.32% |
| 2023 Q3 | -409.16 Thousand USD | 39.92% |
| 2023 Q2 | -681.03 Thousand USD | -26.82% |
| 2022 Q3 | -461.54 Thousand USD | 3.9% |
| 2022 Q2 | -480.28 Thousand USD | 43.08% |
| 2022 FY | -2.02 Million USD | 47.74% |
| 2022 Q1 | -843.72 Thousand USD | -9.05% |
| 2022 Q4 | -317.15 Thousand USD | 31.28% |
| 2021 Q3 | -708.68 Thousand USD | 12.75% |
| 2021 Q4 | -773.69 Thousand USD | -9.17% |
| 2021 FY | -3.86 Million USD | 20.16% |
| 2021 Q1 | -850.24 Thousand USD | 19.71% |
| 2021 Q2 | -812.21 Thousand USD | 4.47% |
| 2020 Q2 | -816.13 Thousand USD | 13.79% |
| 2020 FY | -4.84 Million USD | -92.36% |
| 2020 Q3 | -1.47 Million USD | -81.26% |
| 2020 Q4 | -1.05 Million USD | 28.41% |
| 2020 Q1 | -946.71 Thousand USD | -50.84% |
| 2019 Q4 | -627.64 Thousand USD | -33.59% |
| 2019 Q1 | -540.33 Thousand USD | 19.83% |
| 2019 FY | -2.51 Million USD | 2.78% |
| 2019 Q2 | -477.21 Thousand USD | 11.68% |
| 2019 Q3 | -469.84 Thousand USD | 1.54% |
| 2018 Q4 | -673.97 Thousand USD | -25.79% |
| 2018 Q2 | -635.36 Thousand USD | 14.91% |
| 2018 FY | -2.59 Million USD | 39.61% |
| 2018 Q3 | -535.77 Thousand USD | 15.67% |
| 2018 Q1 | -746.67 Thousand USD | -20.48% |
| 2017 FY | -4.29 Million USD | 53.5% |
| 2017 Q2 | -1.58 Million USD | -7.82% |
| 2017 Q1 | -1.46 Million USD | -3.04% |
| 2017 Q3 | -618.54 Thousand USD | 60.95% |
| 2017 Q4 | -619.73 Thousand USD | -0.19% |
| 2016 FY | -9.22 Million USD | -54.81% |
| 2016 Q2 | -2.73 Million USD | -1.88% |
| 2016 Q3 | -2.39 Million USD | 12.43% |
| 2016 Q1 | -2.68 Million USD | -55.82% |
| 2016 Q4 | -1.42 Million USD | 40.39% |
| 2015 Q4 | -1.72 Million USD | 23.99% |
| 2015 Q2 | -1.24 Million USD | -108.92% |
| 2015 Q1 | -598.13 Thousand USD | 19.84% |
| 2015 FY | -5.96 Million USD | -120.2% |
| 2015 Q3 | -2.26 Million USD | -81.15% |
| 2014 FY | -2.7 Million USD | -125.35% |
| 2014 Q2 | 62.42 Thousand USD | 104.52% |
| 2014 Q1 | -1.38 Million USD | -1560.78% |
| 2014 Q4 | -746.18 Thousand USD | -16.04% |
| 2014 Q3 | -643.06 Thousand USD | -1130.15% |
| 2013 Q3 | -101.16 Thousand USD | 43.73% |
| 2013 Q1 | -837.38 Thousand USD | 78.38% |
| 2013 FY | -1.2 Million USD | 84.13% |
| 2013 Q4 | -83.13 Thousand USD | 17.82% |
| 2013 Q2 | -179.77 Thousand USD | 78.53% |
| 2012 Q1 | -933.77 Thousand USD | -212.23% |
| 2012 Q2 | -995 Thousand USD | -6.56% |
| 2012 Q3 | -1.77 Million USD | -77.94% |
| 2012 FY | -7.57 Million USD | -235.82% |
| 2012 Q4 | -3.87 Million USD | -118.75% |
| 2011 Q2 | -356.16 Thousand USD | 77.11% |
| 2011 FY | -2.25 Million USD | -238.44% |
| 2011 Q4 | 832 Thousand USD | 170.82% |
| 2011 Q3 | -1.17 Million USD | -229.85% |
| 2011 Q1 | -1.55 Million USD | -58.04% |
| 2010 Q1 | 5.59 Million USD | 449.96% |
| 2010 Q2 | -2.45 Million USD | -143.86% |
| 2010 Q3 | -528.2 Thousand USD | 78.48% |
| 2010 FY | 1.62 Million USD | 119.29% |
| 2010 Q4 | -984.46 Thousand USD | -86.38% |
| 2009 FY | -8.44 Million USD | 42.17% |
| 2009 Q1 | -3.16 Million USD | -1.24% |
| 2009 Q2 | -1.94 Million USD | 38.57% |
| 2009 Q3 | -1.72 Million USD | 11.23% |
| 2009 Q4 | -1.59 Million USD | 7.45% |
| 2008 FY | -14.59 Million USD | -12.54% |
| 2008 Q4 | -3.12 Million USD | 0.59% |
| 2008 Q3 | -3.14 Million USD | 20.24% |
| 2008 Q2 | -3.94 Million USD | 9.71% |
| 2008 Q1 | -4.37 Million USD | -33.57% |
| 2007 Q3 | -2.96 Million USD | -3.93% |
| 2007 Q2 | -2.85 Million USD | 26.62% |
| 2007 Q1 | -3.88 Million USD | -12.18% |
| 2007 FY | -12.96 Million USD | 19.22% |
| 2007 Q4 | -3.27 Million USD | -10.48% |
| 2006 Q1 | -4.55 Million USD | -21.95% |
| 2006 Q4 | -3.46 Million USD | 4.74% |
| 2006 Q3 | -3.63 Million USD | 17.36% |
| 2006 FY | -16.05 Million USD | -38.34% |
| 2006 Q2 | -4.39 Million USD | 3.54% |
| 2005 FY | -11.6 Million USD | 0.0% |
| 2005 Q2 | -2.68 Million USD | -1.55% |
| 2005 Q1 | -2.64 Million USD | -171.59% |
| 2005 Q4 | -3.73 Million USD | -47.78% |
| 2005 Q3 | -2.53 Million USD | 5.9% |
| 2004 Q4 | 3.69 Million USD | 344.77% |
| 2004 Q3 | -1.51 Million USD | -14.98% |
| 2004 Q2 | -1.31 Million USD | -50.45% |
| 2004 Q1 | -873.5 Thousand USD | -270.45% |
| 2004 FY | - USD | 100.0% |
| 2003 FY | -1.17 Million USD | -19.56% |
| 2003 Q3 | -474.58 Thousand USD | -457.39% |
| 2003 Q2 | -85.14 Thousand USD | 39.01% |
| 2003 Q1 | -139.59 Thousand USD | 49.37% |
| 2003 Q4 | 512.46 Thousand USD | 207.98% |
| 2002 FY | -982.63 Thousand USD | 63.24% |
| 2002 Q4 | -275.72 Thousand USD | 59.12% |
| 2002 Q3 | -674.4 Thousand USD | -76.25% |
| 2002 Q2 | -382.64 Thousand USD | 54.42% |
| 2002 Q1 | -839.48 Thousand USD | 12.22% |
| 2001 Q1 | -250.06 Thousand USD | 32.72% |
| 2001 Q2 | -740.09 Thousand USD | -195.97% |
| 2001 Q3 | 1.19 Million USD | 261.59% |
| 2001 Q4 | -956.4 Thousand USD | -179.97% |
| 2001 FY | -2.67 Million USD | -1254.26% |
| 2000 Q3 | -1.31 Million USD | -211.78% |
| 2000 FY | -197.4 Thousand USD | 87.83% |
| 2000 Q1 | -657.62 Thousand USD | -55.41% |
| 2000 Q2 | 1.17 Million USD | 278.42% |
| 2000 Q4 | -371.68 Thousand USD | 71.66% |
| 1999 Q2 | -470 Thousand USD | -147.96% |
| 1999 Q4 | -423.15 Thousand USD | -45.32% |
| 1999 Q3 | -291.18 Thousand USD | 38.05% |
| 1999 FY | -1.62 Million USD | 69.16% |
| 1999 Q1 | 980 Thousand USD | 208.89% |
| 1998 Q4 | -900 Thousand USD | 25.0% |
| 1998 Q1 | -1.5 Million USD | -15.38% |
| 1998 Q2 | -1.15 Million USD | 22.8% |
| 1998 Q3 | -1.2 Million USD | -3.63% |
| 1998 FY | -5.25 Million USD | -6.65% |
| 1997 Q4 | -1.3 Million USD | 0.0% |
| 1997 Q3 | -1.3 Million USD | -5.69% |
| 1997 Q2 | -1.22 Million USD | -2.5% |
| 1997 FY | -4.92 Million USD | -18.56% |
| 1997 Q1 | -1.2 Million USD | 7.69% |
| 1996 Q1 | -1.1 Million USD | 0.0% |
| 1996 Q4 | -1.3 Million USD | -8.33% |
| 1996 Q3 | -1.2 Million USD | -25.23% |
| 1996 Q2 | -958.24 Thousand USD | 12.89% |
| 1996 FY | -4.15 Million USD | 38.85% |
| 1995 FY | -6.8 Million USD | -44.68% |
| 1995 Q2 | -2.5 Million USD | -108.33% |
| 1995 Q3 | -1 Million USD | 60.0% |
| 1995 Q4 | -1.1 Million USD | -10.0% |
| 1995 Q1 | -1.2 Million USD | 25.0% |
| 1994 Q3 | -1.5 Million USD | -7.14% |
| 1994 FY | -4.7 Million USD | -487.5% |
| 1994 Q4 | -1.6 Million USD | -6.67% |
| 1994 Q2 | -1.4 Million USD | 0.0% |
| 1994 Q1 | -1.4 Million USD | -40.0% |
| 1993 FY | -800 Thousand USD | 66.67% |
| 1993 Q1 | -200 Thousand USD | -200.0% |
| 1993 Q2 | -300 Thousand USD | -50.0% |
| 1993 Q3 | -900 Thousand USD | -200.0% |
| 1993 Q4 | -1 Million USD | -11.11% |
| 1992 FY | -2.4 Million USD | 7.69% |
| 1992 Q1 | -400 Thousand USD | 50.0% |
| 1992 Q2 | -500 Thousand USD | -25.0% |
| 1992 Q3 | -400 Thousand USD | 20.0% |
| 1992 Q4 | 200 Thousand USD | 150.0% |
| 1991 FY | -2.6 Million USD | -18.18% |
| 1991 Q1 | -700 Thousand USD | -16.67% |
| 1991 Q4 | -800 Thousand USD | 0.0% |
| 1991 Q3 | -800 Thousand USD | 0.0% |
| 1991 Q2 | -800 Thousand USD | -14.29% |
| 1990 Q2 | -600 Thousand USD | 0.0% |
| 1990 FY | -2.2 Million USD | -83.33% |
| 1990 Q3 | -500 Thousand USD | 16.67% |
| 1990 Q4 | -600 Thousand USD | -20.0% |
| 1990 Q1 | -600 Thousand USD | -20.0% |
| 1989 Q4 | -500 Thousand USD | 0.0% |
| 1989 Q2 | -300 Thousand USD | 0.0% |
| 1989 Q3 | -500 Thousand USD | -66.67% |
| 1989 Q1 | -300 Thousand USD | 0.0% |
| 1989 FY | -1.2 Million USD | -344.44% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -197.506% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 43.103% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 107.499% |
| Nascent Biotech, Inc. | -2.08 Million USD | -90.306% |
| Rebus Holdings, Inc. | -1.02 Million USD | -289.509% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 106.1% |
| Qrons Inc. | -789.34 Thousand USD | -403.327% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -528.234% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 93.653% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -856.244% |
| Skye Bioscience, Inc. | -37.64 Million USD | 89.446% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 94.7% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 39.584% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1353.169% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.0% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -37.36% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -118.233% |
| Mesoblast Limited | -87.95 Million USD | 95.483% |
| Marizyme, Inc. | -65.34 Million USD | 93.92% |
| Genus plc | 7.9 Million USD | 150.291% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 63.523% |
| Pharming Group N.V. | -10.54 Million USD | 62.334% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -83.103% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -7.082% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 55.077% |
| ContraFect Corporation | -65.15 Million USD | 93.902% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 18.687% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -129.991% |
| IMV Inc. | -36.48 Million USD | 89.111% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 50.705% |
| MultiCell Technologies, Inc. | -380.07 USD | -1045231.913% |
| ONE Bio Corp. | 8.67 Million USD | 145.79% |
| Accustem Sciences Inc. | -3.74 Million USD | -6.048% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 92.314% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -213.542% |
| Q BioMed Inc. | -2.05 Million USD | -93.607% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -6.429% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -66.871% |
| Biomind Labs Inc. | -1.21 Million USD | -227.179% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 93.348% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -28.088% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 49.729% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -103.822% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -26429.067% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 74.968% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 31.703% |
| GB Sciences, Inc. | -1.36 Million USD | -191.772% |
| Alpha Cognition Inc. | -13.77 Million USD | 71.153% |
| HST Global, Inc. | -146.21 Thousand USD | -2617.32% |
| CSL Limited | 2.64 Billion USD | 100.15% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -126.411% |
| Halberd Corporation | -79.67 Thousand USD | -4886.436% |
| Enzolytics Inc. | -2.17 Million USD | -82.513% |
| Agentix Corp. | -1.37 Million USD | -189.111% |
| Resverlogix Corp. | -3.61 Million USD | -10.055% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -25.274% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.653% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 4154.074% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 157.375% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -31.289% |
| AVAX Technologies, Inc. | -6.41 Million USD | 38.054% |
| Zenith Capital Corp. | -10.59 Million USD | 62.505% |
| Genscript Biotech Corporation | -95.47 Million USD | 95.839% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -16994.024% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 4.171% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -6473.383% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -98.143% |
| Kadimastem Ltd | -3.3 Million USD | -20.124% |
| Helix BioMedix, Inc. | -1.05 Million USD | -276.21% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -4.032% |
| BioStem Technologies, Inc. | -8.48 Million USD | 53.165% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -800.152% |
| LadRx Corporation | 400.44 Thousand USD | 1092.149% |
| Cell Source, Inc. | -5.32 Million USD | 25.337% |
| Regen BioPharma, Inc. | 1.02 Million USD | 488.174% |
| Regen BioPharma, Inc. | 1.02 Million USD | 488.174% |
| NovAccess Global Inc. | -4.76 Million USD | 16.695% |
| Affymax, Inc. | -14.42 Million USD | 72.456% |
| Itoco Inc. | -1.86 Million USD | -112.574% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 10.569% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -138.046% |
| Mobile Lads Corp. | -2.26 Million USD | -75.54% |
| CytoDyn Inc. | -49.84 Million USD | 92.029% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4927.005% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1641.571% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -321.972% |
| SYBLEU INC | -180.3 Thousand USD | -2103.497% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -146.351% |
| International Stem Cell Corporation | -131 Thousand USD | -2932.819% |
| Bioxytran, Inc. | -4.28 Million USD | 7.173% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -7220.521% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -57.02% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 91.735% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -87.937% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -408.78% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -25.41% |
| Neutra Corp. | -233.46 Thousand USD | -1601.751% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 80.42% |
| PureTech Health plc | -65.69 Million USD | 93.953% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 81.318% |
| IXICO plc | -1.17 Million USD | -237.266% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 59.978% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 93.045% |
| CSL Limited | 2.64 Billion USD | 100.15% |
| Cellectis S.A. | -103.17 Million USD | 96.149% |